Get the (ONVO) Report Here
Trade with Jim Cramer 14 Days FREE
The Summit, N.J.-based firm said Thursday that it was discontinuing the GED-0301 (mongersen) Phase 3 Revolve study in Crohn's disease and the extension trial.
There is no questioning the fact that the trend is positive.
But will they run with it?
Is another run in the picture for the 3D bioprinter's shares?
I see no choice but to play defense and prepare for more bleeding.
We had some last-minute games to end the market year.
For such a strong day, the action was dull.
If this market is so great, why are so many traders complaining?
The bears just can't get a claw into this market.
There's already talk of a melt-up move to end the year.
This market is messy and uneven.
Lately they have been useless as indicators of anything.
The bears have the advantage and its best not to fight them.
The action I saw today demands more caution.
The trend to the upside remains quite strong.
Not to be overly negative, but increased awareness can't hurt.
Don't be overly bearish just because the action is 'too good.'
And without a worry in the world.
Follow Real Money's Wall Street Pros to receive real-time investing alerts
Already a Subscriber? Login